Deep Brain Stimulation (DBS) therapy, used in indications including Parkinsonʼs Disease, is an existing market growing at over 10% annually and is Alevaʼs first target market.

 

With Alevaʼs products, neurosurgeons and neurologists will see reduced surgical and follow-up times, patients will benefit from a decrease in debilitating side effects, and payers will see a reduction in cost-of-care.

​

Alevaʼs technology can decrease the complications and side effects associated with DBS therapy.